

SUMMARY OF PERFORMANCE

KEY NATIONAL INDICATORS

A&E INDICATORS

Monitor Indicator and threshold:

	Threshold	Monitoring Period
Maximum of four hours from arrival to admission/ transfer/ discharge	95%	Quarterly

EKHUFT Performance:

Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mch
91.1%	97.3%	97.0%	94.5%	95.8%	94.9%	92.7%	96.5%	93.0%	95.3%	95.3%	95.2%

REFERRAL TO TREATMENT WAITING TIME PERFORMANCE

Monitor Indicator and threshold:

	Threshold	Monitoring Period
Maximum time of 18 weeks from point of referral to treatment in aggregate – admitted.	90%	Quarterly
Maximum time of 18 weeks from point of referral to treatment in aggregate – non-admitted.	95%	Quarterly
Maximum time of 18 weeks from point of referral to treatment in aggregate – patients on an incomplete pathway	92%	Quarterly

EKHUFT Performance:

Pathway	< 18 Weeks	>18 Weeks	Total	% Compliance	52 Week waiters	Backlog Position
Non-Admitted Pathway	9,071	156	9,227	98.3%		
Admitted Pathway	3,081	335	3,416	90.2%		859
Incomplete Pathways	28,096	1,713	29,809	94.3%	0	

Table 3.1 – RTT Position Compliance by Pathway (March 2013)

CANCER TARGETS

Monitor Indicator and threshold:

	Threshold	Monitoring Period
All cancers: 62 day wait for first treatment from: <ul style="list-style-type: none"> Urgent GP referral for suspected cancer NHS cancer screening service referral 	85% 90%	Quarterly
All cancers: 31 day wait for second or subsequent treatment comprising: <ul style="list-style-type: none"> Surgery Anti-cancer drug treatments Radiotherapy 	94% 98% 94%	Quarterly
All cancers: 31 day wait from diagnostics to first treatment	96%	Quarterly
Cancer: two week wait from referral to date first seen comprising: <ul style="list-style-type: none"> All urgent referrals (cancer suspected) For symptomatic breast patients (cancer not initially suspected) 	93% 93%	Quarterly

EKHUFT Performance:

AS AT 07-Apr-14	2 Week Wait		31 Day			62 Day	
	All Cancers	Symptomatic Breast	Diag to First Treat	Surgery	Drug	Urgent GP Referral	Screening Referral
Target 2013/14	93%	93%	96%	94%	98%	85%	90%
Q1	95.24%	94.99%	98.75%	97.08%	100.00%	86.47%	90.91%
Q2	93.12%	88.29%	99.05%	99.17%	100.00%	89.72%	95.59%
Q3	95.22%	93.29%	98.31%	97.89%	98.15%	85.01%	87.77%
January	95.08%	93.04%	94.33%	94.83%	100.00%	78.10%	58.33%
February	97.08%	94.97%	97.81%	95.92%	100.00%	85.89%	78.95%
March*	95.28%	93.75%	98.67%	100.00%	97.44%	93.04%	92.86%
Q4*	95.80%	93.99%	96.80%	96.71%	99.35%	85.16%	77.46%

*unvalidated position

Table 6.1 – Cancer Performance 2013/14